ANGLE plc (GB:AGL) has released an update.
ANGLE plc, a prominent liquid biopsy company, has reported a significant increase in annual revenue to £2.2 million, up from £1.0 million the previous year, despite a net loss of £20.1 million. The company attributes its financial growth to the successful launch of new products and services, including contracts with pharmaceutical giants like Eisai and Crescendo Biologics, and expansion of its global distribution network. With a strong start to 2024, including new pharma contracts and a solid product pipeline, ANGLE is optimistic about its commercial momentum and aims for cashflow breakeven by the end of 2025.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
